// App-Quantinova.ai

P1276 : DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN'S LYMPHOMA

Researchers

Presenter

  • Maya K. Leabman

Principal Investigators

  • Genevive Hernandez

  • Keyu Li

  • Paul R. Hinton

  • John So

  • Ibrahim Qazi

  • Chan Y. Cheah

  • Won Seog Kim

  • Elizabeth Budde

  • Ajay K. Gopal

  • Thomas Manley

  • Chris H. Takimoto

  • Angus M. Sinclair

  • Stephen F. Carroll

  • Bruce A. Keyt

Medical Centers

  • Samsung Medical Center, Seoul, Republic of Korea

  • Samsung Medical Centre,Seoul,Корея, южная

  • University of Washington/Fred Hutchinson Cancer Research

  • Samsung Medical Center, Seoul, Korea

  • Department of Hematology and Hemat

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Samsung Medical Centre,Seoul,Corée, République De

  • Linear Clinical Res

  • Samsung Med Cntr, Korea, Republic of

  • Department of Hematology and Hematopietic Cell Transplantation, City of Hope, Duarte, CA

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • Samsung Medical Center​,Seoul,Corea del Sud

Locations

  • United States

  • United Kingdom

  • Australia

  • Republic of South Korea

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT04082936

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved